These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7686944)

  • 1. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
    Kang CY; Hariharan K; Posner MR; Nara P
    J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.
    Chamat S; Nara P; Berquist L; Whalley A; Morrow WJ; Köhler H; Kang CY
    J Immunol; 1992 Jul; 149(2):649-54. PubMed ID: 1378074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1.
    VanCott TC; Bethke FR; Polonis VR; Gorny MK; Zolla-Pazner S; Redfield RR; Birx DL
    J Immunol; 1994 Jul; 153(1):449-59. PubMed ID: 7515931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T; Kurth R; Norley S
    J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.
    Zhang YJ; Fredriksson R; McKeating JA; Fenyö EM
    Virology; 1997 Nov; 238(2):254-64. PubMed ID: 9400598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the site in CD4 that binds to the HIV envelope glycoprotein.
    Brodsky MH; Warton M; Myers RM; Littman DR
    J Immunol; 1990 Apr; 144(8):3078-86. PubMed ID: 1691226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of HIV-1 by anti-idiotypes to monoclonal anti-CD4. Potential for idiotype immunization against HIV.
    Sutor GC; Dreikhausen U; Vähning U; Jurkiewicz E; Hunsmann G; Lundin K; Schedel I
    J Immunol; 1992 Aug; 149(4):1452-61. PubMed ID: 1500724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
    Boudet F; Theze J; Zouali M
    Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
    Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
    Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two new human monoclonal antibodies against HIV type 1 glycoprotein 120: characterization and neutralizing activities against HIV type 1 strains.
    Février M; Boudet F; Deslandres A; Theze J
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):491-500. PubMed ID: 7543271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.